Purpose: Multiple Myeloma (MM) is a biologically heterogenous plasma-cell disorder. In this study we aimed at dissecting the functional impact on transcriptome of gene mutations, copy- number abnormalities (CNAs), and chromosomal rearrangements (CRs). Moreover, we applied a geno-transcriptomic approach to identify specific biomarkers for personalized treatments. Methods: We analyzed 514 newly diagnosed patients from the IA12 release of the CoMMpass study, accounting for mutations in MM driver genes, structural variants, copy-number segments and raw-transcript counts. We performed an in-silico drug sensitivity screen (DSS), interrogating the DepMap dataset after anchoring cell lines to primary tumor samples using the Celligner algorithm. Results: Immunoglobulin translocations, hyperdiploidy and Chr(1q)gain/amps were associated with the highest number of deregulated genes. Other CNAs and specific gene mutations had a lower but very distinct impact affecting specific pathways. Many recurrent genes showed a hotspot(HS)- specific effect. The clinical relevance of double-hit MM found strong biological bases in our analysis. Bi-allelic deletions of tumor suppressors and chr(1q)-amplifications showed the greatest impact on gene expression, deregulating pathways related to cell-cycle, proliferation and expression of immunotherapy targets. Moreover, our in-silico DSS showed that not only t(11;14) but also chr(1q)gain/amps and CYLD inactivation predicted differential expression of transcripts of the BCL2-axis and response to venetoclax. Conclusions: The MM genomic architecture and transcriptome have a strict connection, led by CNAs and CRs. Gene mutations impacted especially with HS-mutations of oncogenes and bi-allelic tumor suppressor gene inactivation. Finally, a comprehensive geno-transcriptomic analysis allows the identification of specific deregulated pathways and candidate biomarkers for personalized treatments in MM.

Functional impact of genomic complexity on the transcriptome of Multiple Myeloma / B. Ziccheddu, M.C. Da Via, M. Lionetti, A. Maeda, S. Morlupi, M. Dugo, K. Todoerti, S. Oliva, M. D'Agostino, P. Corradini, O. Landgren, F. Iorio, L. Pettine, A. Pompa, M. Manzoni, L. Baldini, A. Neri, F. Maura, N. Bolli. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 27:23(2021 Dec 01), pp. clincanres.4366.2020.6479-clincanres.4366.2020.6490. [10.1158/1078-0432.CCR-20-4366]

Functional impact of genomic complexity on the transcriptome of Multiple Myeloma

M.C. Da Via
Secondo
;
M. Lionetti;A. Maeda;S. Morlupi;K. Todoerti;P. Corradini;L. Pettine;M. Manzoni;L. Baldini;A. Neri;F. Maura
Penultimo
;
N. Bolli
Ultimo
2021

Abstract

Purpose: Multiple Myeloma (MM) is a biologically heterogenous plasma-cell disorder. In this study we aimed at dissecting the functional impact on transcriptome of gene mutations, copy- number abnormalities (CNAs), and chromosomal rearrangements (CRs). Moreover, we applied a geno-transcriptomic approach to identify specific biomarkers for personalized treatments. Methods: We analyzed 514 newly diagnosed patients from the IA12 release of the CoMMpass study, accounting for mutations in MM driver genes, structural variants, copy-number segments and raw-transcript counts. We performed an in-silico drug sensitivity screen (DSS), interrogating the DepMap dataset after anchoring cell lines to primary tumor samples using the Celligner algorithm. Results: Immunoglobulin translocations, hyperdiploidy and Chr(1q)gain/amps were associated with the highest number of deregulated genes. Other CNAs and specific gene mutations had a lower but very distinct impact affecting specific pathways. Many recurrent genes showed a hotspot(HS)- specific effect. The clinical relevance of double-hit MM found strong biological bases in our analysis. Bi-allelic deletions of tumor suppressors and chr(1q)-amplifications showed the greatest impact on gene expression, deregulating pathways related to cell-cycle, proliferation and expression of immunotherapy targets. Moreover, our in-silico DSS showed that not only t(11;14) but also chr(1q)gain/amps and CYLD inactivation predicted differential expression of transcripts of the BCL2-axis and response to venetoclax. Conclusions: The MM genomic architecture and transcriptome have a strict connection, led by CNAs and CRs. Gene mutations impacted especially with HS-mutations of oncogenes and bi-allelic tumor suppressor gene inactivation. Finally, a comprehensive geno-transcriptomic analysis allows the identification of specific deregulated pathways and candidate biomarkers for personalized treatments in MM.
English
Multiple myeloma; personalized medicine; genomics; transcriptomics; BCL2 inhibitors;
Settore MED/15 - Malattie del Sangue
Settore MEDS-09/B - Malattie del sangue
Articolo
Esperti anonimi
Pubblicazione scientifica
Goal 3: Good health and well-being
   spontaneous Evolution and Clonal heterOgeneity in MoNoclonal Gammopathies: from mechanisms of progression to clinical management (bECOMiNG)
   bECOMiNG
   EUROPEAN COMMISSION
   H2020
   817997
1-dic-2021
15-set-2021
American Association of Cancer Research
27
23
clincanres.4366.2020
6479
6490
12
Pubblicato
Periodico con rilevanza internazionale
pubmed
crossref
Aderisco
info:eu-repo/semantics/article
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma / B. Ziccheddu, M.C. Da Via, M. Lionetti, A. Maeda, S. Morlupi, M. Dugo, K. Todoerti, S. Oliva, M. D'Agostino, P. Corradini, O. Landgren, F. Iorio, L. Pettine, A. Pompa, M. Manzoni, L. Baldini, A. Neri, F. Maura, N. Bolli. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 27:23(2021 Dec 01), pp. clincanres.4366.2020.6479-clincanres.4366.2020.6490. [10.1158/1078-0432.CCR-20-4366]
open
Prodotti della ricerca::01 - Articolo su periodico
19
262
Article (author)
Periodico con Impact Factor
B. Ziccheddu, M.C. Da Via, M. Lionetti, A. Maeda, S. Morlupi, M. Dugo, K. Todoerti, S. Oliva, M. D'Agostino, P. Corradini, O. Landgren, F. Iorio, L. P...espandi
File in questo prodotto:
File Dimensione Formato  
Ziccheddu_Clin Cancer Res_2021_Epub.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 831.32 kB
Formato Adobe PDF
831.32 kB Adobe PDF Visualizza/Apri
1078-0432.CCR-20-4366.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.54 MB
Formato Adobe PDF
1.54 MB Adobe PDF Visualizza/Apri
6479.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.5 MB
Formato Adobe PDF
1.5 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/870960
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 22
  • OpenAlex ND
social impact